{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:57:01Z","timestamp":1791327421652,"version":"4.3.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016300","name":"Octapharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016300","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Subcutaneous immunoglobulin (SCIG) preparations are widely used in patients with inborn errors of immunity (IEI), with proven efficacy and good tolerance. We assessed treatment efficacy, safety, and quality of life in a large cohort of IEI patients who switched from intravenous immunoglobulin (IVIG) to SCIG. Our observational study included 200 patients aged 1\u201365 years with IEI. SCIG Cutaquig (16.5%) was administered every 7\u201310 days for at least 12 months via the rapid push method. We assessed the rate of infection, immunoglobulin G (IgG) concentration, adverse events, and quality of life. A total of 8,787 SCIG doses were administered during the study. The rate of infections (per person\/month) during SCIG treatment was 0.05, which was significantly lower compared to 0.19 during the IVIG period (p&amp;lt;0.001). The median trough IgG was 6.9 g\/L on IVIG, compared to 9.0 g\/L during the first six months, and 9.2 g\/L during the next six months on SCIG. Systemic reactions occurred in 12.4% of the IVIG infusions and 1.9% of the SCIG infusions. The total scores on quality of life summary assessments of physical and mental health were higher on SCIG therapy compared with IVIG (p&amp;lt;0.001). At the end of the study, 85.6% of the patients chose to remain on SCIG. Our data suggest that SCIG infusion via the rapid push method is effective, well tolerated, and feasible in large groups of IEI patients, including those in large countries such as Russia.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1598491","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T05:30:16Z","timestamp":1753162216000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["\u0420rospective multicenter study of treatment efficacy, safety, and quality of life in a large cohort of patients with inborn errors of immunity receiving subcutaneous immunoglobulin by the rapid push method"],"prefix":"10.3389","volume":"16","author":[{"given":"Asmik","family":"Avedova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Deripapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Rodina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mukhina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Latysheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Yukhacheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasily","family":"Burlakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nellie","family":"Kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Bogdanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Moiseeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Kuzmenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoya","family":"Nesterenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Deordieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ogneva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Bludova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Roppelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Fomina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Zinovieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Sevostyanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linara","family":"Kalmeteva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilara","family":"Prolygina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyudmila","family":"Barycheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Selezneva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalya","family":"Shakhova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Laba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Vlasova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alla","family":"Gorenkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Timofeeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Trusova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Guseva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalya","family":"Yudina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeniya","family":"Grevtseva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asya","family":"Ibisheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zema","family":"Bambaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Mashkovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Isakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almazia","family":"Shakirova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Selina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Shilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Zubova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Khabaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Kitova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Mandzhieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Starikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Pavlova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Tyulyakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolay","family":"Grachev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Shcherbina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.70962\/jhi.20250003","article-title":"Human inborn errors of immunity: 2024 update on the classification from the International Union of Immunological Societies Expert Committee","volume":"1","author":"Poli","year":"2025","journal-title":"J Hum Immun"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.jaci.2015.04.049","article-title":"Practice parameter for the diagnosis and management of primary immunodeficiency","volume":"136","author":"Bonilla","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-006-9021-7","article-title":"Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases","volume":"26","author":"Ochs","year":"2006","journal-title":"J Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2217\/imt.14.54","article-title":"Immunoglobulin replacement therapy for primary immunodeficiencies","volume":"6","author":"Peter","year":"2014","journal-title":"Immunotherapy"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-009-9352-2","article-title":"Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis","volume":"30","author":"Shapiro","year":"2010","journal-title":"J Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/pai.2013.24.issue-1","article-title":"Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics","volume":"24","author":"Shapiro","year":"2013","journal-title":"Pediatr Allergy Immunol"},{"key":"B7","unstructured":""},{"key":"B8","unstructured":""},{"key":"B9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.clim.2011.06.002","article-title":"Efficacy and safety of Hizentra\u00ae in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy","volume":"141","author":"Jolles","year":"2011","journal-title":"Clin Immunol"},{"key":"B10","article-title":"Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy","volume":"22","author":"Krishnarajah","year":"2016","journal-title":"Am J Manag Care"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-011-9588-5","article-title":"Efficacy and safety of subcutaneous Vivaglobin\u00ae replacement therapy in previously untreated patients with primary immunodeficiency: a prospective, multicenter study","volume":"31","author":"Borte","year":"2011","journal-title":"J Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-011-9512-z","article-title":"Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease","volume":"31","author":"Wasserman","year":"2011","journal-title":"J Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-023-01509-4","article-title":"Subcutaneous immunoglobulin 16.5% (Cutaquig\u00ae) in primary immunodeficiency disease: safety, tolerability, efficacy, and patient experience with enhanced infusion regimens","volume":"43","author":"Gupta","year":"2023","journal-title":"J Clin Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-016-0327-9","article-title":"Efficacy, Safety, and pharmacokinetics of a novel human immune globulin subcutaneous, 20 in patients with primary immunodeficiency diseases in North America","volume":"36","author":"Suez","year":"2016","journal-title":"J Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-010-9423-4","article-title":"Efficacy and safety of a new 20 immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency","volume":"30","author":"Hagan","year":"2010","journal-title":"J Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00040","article-title":"Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig\u00ae]) in the treatment of patients with primary immunodeficiencies","volume":"10","author":"Kobayashi","year":"2019","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2217\/imt-2020-0012","article-title":"Efficacy and safety of octanorm (cutaquig \u00ae) in adults with primary immunodeficiencies with predominant antibody deficiency: aprospective, open-label study","volume":"2","author":"Latysheva","year":"2020","journal-title":"Immunotherapy"},{"key":"B18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/cei\/uxac092","article-title":"Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig\u00ae) in the treatment of patients with primary immunodeficiencies","volume":"210","author":"Kobayashi","year":"2022","journal-title":"Clin Exp Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2013.09.012","article-title":"Adverse effects of IgG therapy","volume":"1","author":"Berger","year":"2013","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-015-0270-1","article-title":"Subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: the VISPO prospective multicenter study","volume":"35","author":"Vultaggio","year":"2015","journal-title":"Clin Drug Investig"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-015-0190-0","article-title":"Subcutaneous immunoglobulin replacement therapy with hizentra\u00ae is safe and effective in children less than 5 years of age","volume":"35","author":"Patel","year":"2015","journal-title":"J Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2012.04594.x","article-title":"Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy","volume":"169","author":"Orange","year":"2012","journal-title":"Clin Exp Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2019-0057","article-title":"Safety and tolerability of subcutaneous immunoglobulin 20% in primary immunodeficiency diseases from two continents","volume":"11","author":"Suez","year":"2019","journal-title":"Immunotherapy"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-019-00705-5","article-title":"Quality of life differences for primary immunodeficiency patients on home SCIG versus IVIG","volume":"39","author":"Anterasian","year":"2019","journal-title":"J Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-023-01507-6","article-title":"Quality of life evaluation in Saudi Arabian pediatric patients with primary immunodeficiency diseases receiving 20% Subcutaneous igG infusions at home","volume":"43","author":"Al-Saud","year":"2023","journal-title":"J Clin Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2022.108938","article-title":"Subcutaneous Gammanorm\u00ae by pump or rapid push infusion: Impact of the device on quality of life in adult patients with primary immunodeficiencies","volume":"236","author":"Warnatz","year":"2022","journal-title":"Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s10875-018-0583-y","article-title":"Successful treatment with SCIG of a child with refractory chronic ITP","volume":"39","author":"Karastaneva","year":"2019","journal-title":"J Clin Immunol"},{"key":"B28","article-title":"Facilitated subcutaneous immunoglobulin (fSCIg) in autoimmune cytopenias associated with common variable immunodeficiency","volume":"19","author":"Pedini","year":"2017","journal-title":"Isr Med Assoc J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.24287\/1726-1708-2023-22-2-92-97","article-title":"Experience with the use of immunoglobulin for subcutaneous administration (Hizentra) in the treatment of patients with primary immunodeficiency disease","volume":"22","author":"Avedova","year":"2023","journal-title":"Pediatr Hematology\/Oncol Immunopathol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1598491\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T05:30:17Z","timestamp":1753162217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1598491\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2025.1598491"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1598491","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"article-number":"1598491"}}